Oncothyreon Inc., of Seattle, priced concurrent but separate underwritten offerings of 13.5 million common shares at $1.50 apiece, for expected proceeds of approximately $20 million, and 1,333 shares of its series B convertible preferred stock at $1,500 apiece, for expected proceeds of about $2 million.